Kura Oncology, Inc. (KURA)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
10.91 USD
-0.54
(-4.716%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:42 a.m. EDT
The investment case here is fundamentally broken despite the recent index reclassification hype. While the company boasts a fortress balance sheet with massive cash reserves relative to debt, the business itself is hemorrhaging value; gross margins are deeply negative, free cash flow is a massive outflow, and the stock has suffered a catastrophic 71% drop in the trailing twelve months. This price collapse is not a 'value trap' waiting for a turnaround; it is a reflection of a product that failed to gain traction and a pipeline that has disappointed investors repeatedly. The recent shift to growth indices was a mechanical event that temporarily boosted sentiment, but the underlying reality remains bleak. With no dividend to provide income and a statistical forecast showing zero directional bias due to low confidence, there is no rational entry point for capital preservation. The options market confirms this fear, with traders aggressively buying protection at levels significantly higher than today's price, betting on further downside before any potential recovery. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.083124 |
| AutoETS | 0.084173 |
| MSTL | 0.085771 |
| AutoTheta | 0.088729 |
| MSTL_97 | 0.092707 |
| MSTL_70_97 | 0.096674 |
| MSTL_70 | 0.107493 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 21.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.069 |
| Excess Kurtosis | -0.52 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 22.499 |
| Revenue per Share | 0.814 |
| Market Cap | 968,528,320 |
| Forward P/E | -4.20 |
| Beta | 0.35 |
| Website | https://kuraoncology.com |
As of July 11, 2026, 3:42 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest concentrated at strikes above the current price ($12-$17), while call activity remains thin and skewed toward lower strikes. The implied volatility surface shows elevated premiums for downside protection expiring in August and October, suggesting a market expectation of continued volatility or further weakness rather than a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.77977157 |
| Address1 | 4,930 Directors Place |
| Address2 | Suite 500 |
| All Time High | 43.0 |
| All Time Low | 2.5 |
| Ask | 13.92 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,808,390 |
| Average Daily Volume3 Month | 1,793,093 |
| Average Volume | 1,793,093 |
| Average Volume10Days | 1,808,390 |
| Beta | 0.35 |
| Bid | 10.0 |
| Bid Size | 4 |
| Board Risk | 8 |
| Book Value | 1.215 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.91 |
| Current Ratio | 6.146 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 11.33 |
| Day Low | 10.855 |
| Debt To Equity | 22.499 |
| Display Name | Kura Oncology |
| Earnings Call Timestamp End | 1,778,617,800 |
| Earnings Call Timestamp Start | 1,778,617,800 |
| Earnings Timestamp | 1,778,616,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -316,600,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.301 |
| Enterprise To Revenue | 5.751 |
| Enterprise Value | 411,978,336 |
| Eps Current Year | -3.45667 |
| Eps Forward | -2.59778 |
| Eps Trailing Twelve Months | -3.35 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.9274 |
| Fifty Day Average Change | 0.9826002 |
| Fifty Day Average Change Percent | 0.09897861 |
| Fifty Two Week Change Percent | 77.97716 |
| Fifty Two Week High | 12.49 |
| Fifty Two Week High Change | -1.5799999 |
| Fifty Two Week High Change Percent | -0.1265012 |
| Fifty Two Week Low | 5.45 |
| Fifty Two Week Low Change | 5.46 |
| Fifty Two Week Low Change Percent | 1.0018349 |
| Fifty Two Week Range | 5.45 - 12.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,442,410,200,000 |
| Float Shares | 70,415,826 |
| Forward Eps | -2.59778 |
| Forward P E | -4.19974 |
| Free Cashflow | -129,832,496 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 260 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -2.63884 |
| Gross Profits | -189,044,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0143 |
| Held Percent Institutions | 0.96844 |
| Implied Shares Outstanding | 88,774,365 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California. |
| Long Name | Kura Oncology, Inc. |
| Market | us_market |
| Market Cap | 968,528,320 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_282774456 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -294,569,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 968,084,450 |
| Number Of Analyst Opinions | 12 |
| Open | 11.165 |
| Operating Cashflow | -77,985,000 |
| Operating Margins | -4.31508 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 500 8800 |
| Pre Market Change | 0.13000011 |
| Pre Market Change Percent | 1.1915685 |
| Pre Market Price | 11.04 |
| Pre Market Time | 1,784,030,717 |
| Previous Close | 11.45 |
| Price Eps Current Year | -3.1562166 |
| Price Hint | 2 |
| Price To Book | 8.9794235 |
| Price To Sales Trailing12 Months | 13.5195675 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.857 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | -0.54 |
| Regular Market Change Percent | -4.71616 |
| Regular Market Day High | 11.33 |
| Regular Market Day Low | 10.855 |
| Regular Market Day Range | 10.855 - 11.33 |
| Regular Market Open | 11.165 |
| Regular Market Previous Close | 11.45 |
| Regular Market Price | 10.91 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,563,177 |
| Return On Assets | -0.28445 |
| Return On Equity | -1.2474099 |
| Revenue Growth | 0.295 |
| Revenue Per Share | 0.814 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 88,774,365 |
| Shares Percent Shares Out | 0.17 |
| Shares Short | 15,092,162 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 13,592,010 |
| Short Name | Kura Oncology, Inc. |
| Short Percent Of Float | 0.1745 |
| Short Ratio | 7.94 |
| Source Interval | 15 |
| State | CA |
| Symbol | KURA |
| Target High Price | 76.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 31.16667 |
| Target Median Price | 28.0 |
| Total Cash | 580,822,976 |
| Total Cash Per Share | 6.543 |
| Total Debt | 24,273,000 |
| Total Revenue | 71,639,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.5778 |
| Two Hundred Day Average Change | 1.3322 |
| Two Hundred Day Average Change Percent | 0.13909249 |
| Type Disp | Equity |
| Volume | 1,563,177 |
| Website | https://kuraoncology.com |
| Zip | 92,121 |